Tools
Tools
Platt, L, Minozzi, S, Reed, J, Vickerman, P, Hagan, H, French, C, Jordan, A, Degenhardt, L, Hope, V, Hutchinson, S, Maher, L, Palmateer, N, Taylor, A, Bruneau, J and Hickman, M (2017) Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction, 113 (3). pp. 545-563. ISSN 0965-2140
|
Text
M:\My Documents\Work\My papers\Platt et al Addiction 2017 accepted.pdf - Accepted Version Download (764kB) | Preview |
Abstract
AIMS: To estimate the effects of needle syringe programmes (NSP) and opioid substitution therapy (OST), alone or in combination, for preventing acquisition of Hepatitis C virus (HCV) in people who inject drugs (PWID). METHODS: Systematic review and meta-analysis. Bibliographic databases were searched for studies measuring concurrent exposure to current OST (within last 6 months) and/or NSP and HCV incidence among PWID. High NSP coverage was defined as regular NSP attendance or ≥100% coverage (receiving sufficient or greater number of needles/syringes per reported injecting frequency). Studies were assessed using the Cochrane risk of bias in non-randomised studies tool. Random effects models were used in meta-analysis. RESULTS: We identified 28 studies (n=6279) in North America (13), UK (5), Europe (4), Australia (5), and China (1). Studies were at moderate (2), serious (17) critical (7) and non-assessable risk of bias (2). Current OST is associated with 50% (risk ratio (RR) 0.50 95% CI 0.40-0.63) reduction in HCV acquisition risk, consistent across region and with low heterogeneity (I(2) =0, p=0.889). Weaker evidence was found for high NSP coverage (RR=0.79 95% CI 0.39-1.61) with high heterogeneity (I(2) =77%, p=0.002). After stratifying by region, high NSP coverage in Europe was associated with a 56% reduction in HCV acquisition risk (RR=0.44, 95% CI 0.24-0.80) with low heterogeneity (I(2) =12.3%, p=0.337) but not in North America (RR=1.58, I(2) =89.5%, p=<0.001). Combined OST/NSP is associated with a 76% reduction in HCV acquisition risk (RR=0.24 95% CI=0.07-0.89, I(2) =80% p=0.007). According to GRADE criteria, the evidence on OST and combined OST/NSP is low quality while NSP is very low. CONCLUSIONS: Opioid substitution therapy reduces risk of hepatitis C acquisition and is strengthened in combination with needle syringe programmes. There is weaker evidence for the impact of needle syringe programmes alone, although stronger evidence that high coverage is associated with reduced risk in Europe.
| Item Type: | Article |
|---|---|
| Additional Information: | This is the accepted version of the following article: Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., Maher, L., Palmateer, N., Taylor, A., Bruneau, J., and Hickman, M. (2017) Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction, doi: 10.1111/add.14012. which has been published in final form at http://dx.doi.org/10.1111/add.14012 |
| Uncontrolled Keywords: | 11 Medical And Health Sciences, 17 Psychology And Cognitive Sciences |
| Subjects: | R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine |
| Divisions: | Public Health Institute |
| Publisher: | Wiley |
| Related URLs: | |
| Date Deposited: | 14 Sep 2017 11:03 |
| Last Modified: | 04 Sep 2021 11:13 |
| DOI or ID number: | 10.1111/add.14012 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/7095 |
 |
View Item |